31
Kent W Neuenschwander, Anthony C Scotese: HMG-COA reductase inhibitors. Rhone Poulenc Rorer Pharmaceuticals, Imre, James A Nicholson, March 19, 1991: US05001128 (16 worldwide citation)

Disclosed are novel 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids and esters derived therefrom and pharmaceutically acceptable salts thereof.


32
Peter E Grebow, Herschel H Li, Lewis J Klunk Jr: Intranasal calcitonin formulations. Rhone Poulenc Rorer Pharmaceuticals, Imre, James A Nicholson, June 25, 1991: US05026825 (16 worldwide citation)

Disclosed are intranasal formulations comprising calcitonin and .sup..DELTA. -aminolevulinic acid in a pharmaceutically acceptable excipient.


33
John W Ullrich, Kent W Neuenschwander, John R Regan: Novel HMG-COA reductase inhibitors. Rhone Poulenc Rorer Pharmaceuticals, Imre, James A Nicholson, February 12, 1991: US04992429 (16 worldwide citation)

Disclosed are novel substituted cyclohexenyl phosphinylhydroxybutyrates as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula: ##STR1## and pharmaceutically acceptable salts thereof.


34
John R Regan, Kent W Neuenschwander: Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors. Rhone Poulenc Rorer Pharmaceuticals, Imre, James A Nicholson, March 19, 1991: US05001144 (15 worldwide citation)

Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof.


35
Bruce F Molino, Paul R Darkes, William R Ewing: Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists. Rhone Poulenc Rorer Pharmaceuticals, Paul R Darkes, Martin F Savitzky, November 10, 1992: US05162336 (15 worldwide citation)

Disclosed are tetrahydro-pyrido-indoles having the general formula ##STR1## which are antagonists towards the neuropeptides cholexystokinin and gastrin processing valuable activities for the treatment of cholecystokinin or gastrin-related disorders of the gastrointestinal, central nervous and appeti ...


36
Michael E Hrinda, Rose D Alisa, George C Tarr: Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions. Rhone Poulenc Rorer Pharmaceuticals, Rosanne Goodman, Martin F Savitzky, April 5, 1994: US05300433 (14 worldwide citation)

The present invention provides a fail-safe combination of chemical and physical means for rendering a blood product which comprises a labile blood protein free of viruses without incurring protein denaturation. The blood product is contacted with an effective amount of a selected chemical disinfecta ...


37
Fu Chih Huang, Wan K Chan, Charles A Sutherland, Robert A Galemmo Jr: Substituted naphthylene compounds exhibiting selective leukotriene B.sub.4 antagonist activity. Rhone Poulenc Rorer Pharmaceuticals, James A Nicholson, Martin F Savitzky, Raymond S Parker III, November 21, 1995: US05468898 (13 worldwide citation)

This invention relates to bicyclic aryl compounds having selective LTB.sub.4 antagonist properties and comprising an amido substituent, a substituent group having a terminal carboxylic acid or derivative thereof and a lipophilic substituent, and to methods for the treatment of disorders which result ...


38
John W Ullrich, Terence J Kiesow, Kent W Neuenschwander, Keith S Learn, William P Dankulich, Anthony C Scotese: Cycloalkyl amine bis-aryl squalene synthase inhibitors. Rhone Poulenc Rorer Pharmaceuticals, James A Nicholson, Masrtin F Savitzky, Raymond S Parker, September 19, 1995: US05451596 (13 worldwide citation)

This invention relates to a class of novel polycyclic compounds containing a cycloalkyl ring having substituted thereon a primary amine and which is further linked or bridged to two mono- and/or bicyclic rings and which reduces levels of serum cholesterol in the body without significantly reducing m ...


39
Henry W Pauls, Yong Mi Choi, Dilip V Amin: Phosphonate derivatives of lipophilic amines. Rhone Poulenc Rorer Pharmaceuticals, James A Nicholson, Julie K Smith, Martin F Savitzky, August 15, 1995: US05441946 (13 worldwide citation)

This invention relates to a class of novel phosphonate derivatives of lipophilic amines which exhibit squalene synthase inhibition properties. More specifically the compounds are bis aryl cycloalkylamino and azacycloalkyl phosphonates. Compounds of this invention reduce levels of serum cholesterol i ...


40
Ramila Philip, Jane Lebkowski: Adeno-associated viral (AAV) liposomes and methods related thereto. Rhone Poulenc Rorer Pharmaceuticals, Synnestvedt & Lechner, January 19, 1999: US05861314 (12 worldwide citation)

A composition for genetic manipulation which comprises a liposome comprised of lipid material, and adeno-associated viral (AAV) material. Typically, the AAV material is plasmid, and comprises a terminal repeat of the AAV genome. Methods are disclosed for introducing genetic material into cells by us ...